<DOC>
	<DOC>NCT01602120</DOC>
	<brief_summary>This extension to study CFD4870g (GX01456) will assess the long-term safety and tolerability of repeated intravitreal administration of FCFD4514S in patients with geographic atrophy. Patients are eligible to participate who have completed the 18 month treatment assignment for study CFD4870g (GX01456), and meet GX28198 eligibility criteria. The anticipated time on study treatment is 18 months.</brief_summary>
	<brief_title>An Extension Study to Evaluate the Long-Term Safety of FCFD4514S in Patients With Geographic Atrophy</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Geographic Atrophy</mesh_term>
	<criteria>Previous enrollment and completion of study CFD4870g (GX01456) without early treatment discontinuation Sufficiently clear ocular media, adequate pupillary dilation, and fixation Early treatment and/or study discontinuation prior to completion of study CFD4870g (GX01456) Vitrectomy surgery, submacular surgery, or other surgical intervention for AMD in the study eye Subfoveal focal laser photocoagulation in the study eye Treatment with Visodyne, externalbeam radiation therapy, or transpupillary thermotherapy in the study eye Intravitreal drug delivery other than FCFD4514S in the study eye Active wet AMD in either eye that requires antiVEGF treatment</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>